Quantcast

Systemic Lupus Erythematosus (SLE) Epidemiology 2022 Forecasts in a New Research Report at ReportsnReports.com

August 27, 2013

This EpiCast report (http://www.reportsnreports.com/reports/267627-epicast-report-systemic-lupus-erythematosus-epidemiology-forecast-to-2022.html ) says Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease of multifactorial origin that can affect any organ or organ systems, resulting in a broad spectrum of clinical manifestations ranging from dermatological involvement to multi-organ failure with episodes of relapses and remissions.

Dallas, Texas (PRWEB) August 27, 2013

The systemic lupus erythematosus report says that 2012 had 452,053 diagnosed prevalent cases of SLE in the 7MM, with approximately 60% of the diagnosed prevalent cases (265,562) in the US alone. The research, “EpiCast Report: Systemic Lupus Erythematosus Epidemiology Forecast to 2022,” forecasts that there will be 488,769 diagnosed prevalent cases of SLE in the 7MM by 2022, with an overall average annual growth rate (AGR) of 0.81% during the forecast period. It forecasts an increase in the diagnosed prevalent cases.

For this research, data from country-specific studies published in peer-reviewed journals and governmental documents was utilized to provide the age- and sex-specific prevalent cases of diagnosed SLE in the respective markets. The forecast methodology and disease diagnosis criteria were consistent across all of the 7MM to allow for a meaningful comparison among them. The SLE prevalent case forecast followed the 1982 American College of Rheumatology classification and the LN cases were segmented according to the WHO 1982 classification.

Order a copy of this report at http://www.reportsnreports.com/Purchase.aspx?name=267627 .

The disease has unpredictable natural course and high rates of morbidity and death The incidence and prevalence of SLE varies globally and the variation is attributed to a combination of elements such as the characteristics of the population studied, sex, ethnicity, geographical locations, occupational factors, familial traits, time period involved, and the diagnostic criteria used. Lupus nephritis (LN) or lupus glomerulonephritis is a serious complication of SLE in which the kidneys are affected.

The Systemic Lupus Erythematosus (SLE) EpiCast Report provides an overview of the risk factors and global trends for SLE for the seven major markets (7MM; US, France, Germany, Italy, Spain, UK, and Japan). It provides the 10-year epidemiological forecast of the diagnosed prevalent cases of SLE segmented by sex and age and the diagnosed prevalent cases of lupus nephritis (LN) for the 7MM. The prevalent cases of LN in the US, France, Germany, Italy, Spain, and UK are further segmented by severity class (Class I–VI). The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy this report:

  • Develop business strategies by understanding the trends shaping and driving the global SLE market.
  • Quantify patient populations in the global SLE to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups, sex, and LN class that present the best opportunities for SLE therapeutics in each of the markets covered.
  • Identify the percentage of LN prevalent cases in each severity class.

List of Tables covered in this report

Table 1: The 1982 Revised ARC Criteria For Classification of Systemic Lupus Erythematosus 9

Table 2: Risk Factors Associated with SLE 10

Table 3: World Health Organization Morphologic Classification of Lupus Nephritis (Modified in 1982) 21

Table 4: Sources of Prevalence Data Used in this Analysis 22

Table 5: 7MM, Prevalent Cases of Diagnosed SLE, All Ages, Both Sexes, N, Select Years 2012–2022 35

Table 6: 7MM, Prevalent Cases of Diagnosed SLE, by Age, Both Sexes, N, Row (%), 2012 37

Table 7: 7MM, Prevalent Cases of Diagnosed SLE, All Ages, by Sex, N, Row (%), 2012 38

Table 8: 7MM, Prevalent Cases of Diagnosed LN, All Ages, Both Sexes, N, Select Years 2012–2022 42

Table 9: 6MM, Prevalent Cases in the Different Classes of LN, All Age, Both Sexes, N, Row (%), 2012 43

List of Figures provided in this research

Figure 1: 7MM, Prevalent Cases of Diagnosed SLE, All Ages, Both Sexes, N, 2012–2022 35

Figure 2: 7MM, Prevalent Cases of Diagnosed SLE, by Age, Both Sexes, N, Row (%), 2012 37

Figure 3: 7MM, Prevalent Cases of Diagnosed SLE, All Ages, Both Sexes, 2012 39

Figure 4: 7MM, Age-Standardized Prevalence (%) of Diagnosed SLE, All Ages, by Sex, 2012 40

Figure 5: 7MM, Prevalent Cases of Diagnosed LN, All Ages, Both Sexes, N, 2012–2022 42

Figure 6: 6MM, Prevalent Cases of LN, by Class, All Ages, Both Sexes, 2012 44

Complete EpiCast Report: Systemic Lupus Erythematosus Epidemiology Forecast to 2022 available at http://www.reportsnreports.com/reports/267627-epicast-report-systemic-lupus-erythematosus-epidemiology-forecast-to-2022.html .

More reports on Pharmaceuticals market available at http://www.reportsnreports.com/market-research/pharmaceuticals/ and on the Healthcare market available at http://www.reportsnreports.com/market-research/healthcare/ .

About Us:

ReportsnReports.com ( http://www.reportsnreports.com/ ) is an online market research reports library of 350,000+ in-depth studies of over 5000 micro markets. We provide 24/7 online and offline support service to our customers. Explore more reports at http://www.sandlerresearch.org/ .

For the original version on PRWeb visit: http://www.prweb.com/releases/systemic-lupus-epicast/erythematosus-2022-report/prweb11064421.htm


Source: prweb



comments powered by Disqus